DUBLIN, June 12, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/3c9pm9/research_report) has announced the addition of the "Research Report on China's Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017" report to their offering.
Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion is possibly related to race and regions.
In China, the PH morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the relatively high morbidity among patients suffering from diseases in the nervous system, respiratory system and reproductive system. The morbidity of people with a family history of PH is over 50%.
Only under severe symptoms will PH patients need the surgical treatment. In most cases, the long-term drug treatment is adopted. Currently, the common clinical drugs include receptor blocking agents, antiandrogen drugs, traditional Chinese medicine preparations, plant preparations, etc.
In 2012, the market size of China's hospital-use anti-PH drugs reached CNY 3.67 billion, increasing by 12.6% YOY.
Four drug varieties, namely, Finasteride, Tamsulosin, Doxazosin and Cernilton dominate China's hospital-use anti-PH drug market. In 2011, it controlled nearly 80% of hospital-use anti-PH drug market nationwide.
In the coming years, a large group of branded drugs will successively lose pat
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved